ClinicalTrials.gg
CompletedNCT03482934Updated Sep 29, 2021

Predictors of Left Ventricular Hypertrophy in Hypertensive Patients in Assiut Governorate

An observational study in HTN and Hypertrophy, Left Ventricular, sponsored by Assiut University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-29.

Sponsored by Assiut University · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
300
Ages
18 Years and older
Sex
All
01

Study summary

To recognize predictors of left ventricular hypertrophy in hypertensive patients in Assiut government \& to recognize the prognostic effect of central blood pressure measurement versus office brachial blood pressure measurement.

Read the detailed description

Many cohort studies have demonstrated that hypertension is a strong risk factor for total mortality and cardiovascular disease (CVD) in both developing and developed countries.

Although brachial blood pressure (BP) mea¬surements have been used for over a century more and more data suggest that measuring of brachial BP has important limitations. First, a few office BP readings may not be representa¬tive of BP during a patient's daily life. Second, brachial BP may differ from systolic BP mea¬sured at the level of the ascending aorta, i.e. central BP, which is responsible for left ventri¬cle afterload and determines blood flow through coronary and brain arteries .

Recent data from the Strong Heart Study confirm earlier results from smaller studies on high-risk patients that central pulse pressure is superior to brachial pulse pressure in the prediction of further cardiovascular events.

The results of the Conduit Artery Function Evaluation (CAFE) study reminded clinicians of the importance of CBP. Those results demonstrated significant differences in CBP (central SBP and PP) between patient groups treated with different antihypertensive regimens even though peripheral BP levels were comparably lowered, and suggested the potential superiority of CBP to cuff brachial BP in cardiovascular prognostic predictive value in hypertensive patients.

Modifiable risk factors for CVD that are common among adults with hypertension include cigarette smoking/tobacco smoke exposure, DM, dyslipidemia (including high levels of low-density lipoprotein cholesterol or hypercholesterolemia, high levels of triglycerides, and low levels of high-density lipoprotein cholesterol), overweight/obesity, physical inactivity/low fitness level, and unhealthy diet .

There are clear examples around the world of ethnic variations in response to drug therapies epitomized by the benefits of thiazide diuretics and calcium channel blockers in lowering BP in blacks and perhaps in older people of all races, whereas blockers of the renin angiotensin system and β-adrenoceptor receptor blockers are just as effective in some other populations.

Urbanization is a factor that profoundly affects BP patterns. In developed countries, hypertension is more common in rural populations than in urban. This pattern is reversed in developing, lower-, and middle-income countries where the first impact of rising rates of hypertension is seen in urban communities.

02

Conditions studied

  • HTN
  • Hypertrophy, Left Ventricular
03

In context

Hypertrophy, Left Ventricular

162 studies on the registry are indexed under Hypertrophy, Left Ventricular; 28 are open to participants now.

This study's enrollment of 300 is above the median of 198 across 60 observational studies indexed under Hypertrophy, Left Ventricular.

Browse Hypertrophy, Left Ventricular studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hypertensive patient recorded in our outpatient clinic during the last two years will be included retrospectively \& new hypertensive patients presenting to our outpatient clinic will be included prospectively for 1 year .

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hypertensive patient recorded in our outpatient clinic during the last two years will be included retrospectively \& new hypertensive patients presenting to our outpatient clinic will be included prospectively for 1 year .

Exclusion criteria

Exclusion Criteria:

  • Patient aged less than 18 year old.
  • Patients from outside Assiut government .
  • Ischemic heart diasease .
  • Heart failure .
  • Cerebrovascular stroke .
  • Diabetes mellitus .
  • Patients on regular dialysis .
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
300 participants (actual)
Patient registry
No

Groups and cohorts

  • hypertensive patients

    Device: sphygmomanometer · Device: mobilogragh · Diagnostic Test: ECG · Diagnostic Test: Echocardiography

Interventions

  • Devicesphygmomanometer

    device used for measurement of brachial blood pressure

  • Devicemobilogragh

    device used for measurement of central blood pressure

  • Diagnostic testECG

    Electrocardiogram

  • Diagnostic testEchocardiography

    Echocardiography

06

What researchers measure

Primary outcomes

  1. Correlation between brachial blood pressure (measured by sphygmomanometer ) and left ventricular mass index measured by echocardiography to recognize predictors of left ventricular hypertrophy in HTN patients

    Time frame: baseline

  2. Correlation between non invasive central blood pressure (measured by mobilograph ) and left ventricular mass index (measured by echocardiography) to recognize predictors of left ventricular hypertrophy in HTN patients

    Time frame: Base line

07

Study locations

1 site
  • Assiut university of medicine
    Assiut, Egypt
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Sep 2020, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2018
First posted
Mar 29, 2018
StartActual
Oct 1, 2019
Primary completionActual
Sep 30, 2020
CompletionActual
Sep 30, 2020
Last update
Sep 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03482934
Lead sponsor
Assiut University
Responsible party
Nardeen Beshay (Principal investigator, Assiut University) — Principal investigator
First posted
Mar 29, 2018
Start date
Oct 1, 2019
Primary completion
Sep 30, 2020
Completion
Sep 30, 2020
Last update
Sep 29, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion